Ruben De Kanter

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Deriving clearance and bioavailability from oral clinical PK studies with information on fraction absorbed, including radiolabeled mass-balance studies.

Deriving clearance and bioavailability from oral clinical PK studies with information on fraction absorbed, including radiolabeled mass-balance studies.

Journal: Journal of pharmaceutical sciences

Published: June 29, 2026

Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter.

Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter.

Journal: Journal of medicinal chemistry

Published: March 04, 2026

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D.

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D.

Journal: Journal of medicinal chemistry

Published: July 10, 2025

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Journal: ChemMedChem

Published: February 13, 2025

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Journal: ChemMedChem

Published: February 13, 2025

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.

Journal: Journal of medicinal chemistry

Published: May 10, 2024

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Journal: Nature

Published: July 26, 2023

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Journal: Cancer discovery

Published: February 07, 2022

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Journal: Journal of medicinal chemistry

Published: November 09, 2017

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Journal: Chimia

Published: October 27, 2017

The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.

The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: July 25, 2017

S1P1 Modulator-Induced G αi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo.

S1P1 Modulator-Induced G αi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo.

Journal: Molecular pharmacology

Published: April 25, 2017

Showing 1-12 of 26

Last Updated: 09/26/2026